Nuveen
GILD icon

Nuveen’s Gilead Sciences GILD Stock Holding History

Nuveen’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,000
Closed -$748K – 3311
2020
Q1 		$748K Buy
+10,000
New +$691K ﹤0.01% 2631

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen's GILD Position: Q2 2026 in Review

Nuveen increased its Gilead Sciences (GILD) stake by 6.4% in Q2 2026, buying an estimated $66.3M and bringing the position to 8,336,930 shares worth $1.05B. The position accounts for 0.25% of the portfolio, ranked #77.

Nuveen first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.09B in Q1 2026. 2,290 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Nuveen held 8,336,930 shares of Gilead Sciences worth $1.05B as of Q2 2026.
  • Nuveen bought 503,366 Gilead Sciences shares in Q2 2026, an estimated $66.3M.
  • Gilead Sciences made up 0.25% of Nuveen's portfolio in Q2 2026, its #77 holding.
  • Nuveen first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Nuveen's Gilead Sciences position peaked at $1.09B in Q1 2026.
  • 2,290 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.